Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 14/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21083532 | 0.85 | LTB4R2 (0.47) | LTB4R2ACHEAGTR1 | |
| SCHEMBL29726839 | 0.85 | LTB4R2 (0.45) | LTB4R2ACHEAGTR1 | |
| SCHEMBL21083851 | 0.85 | LTB4R2 (0.45) | LTB4R2ACHEAGTR1 | |
| SCHEMBL27191042 | 0.84 | LTB4R2 (0.41) | LTB4R2ACHEAGTR1 | |
| SCHEMBL21084019 | 0.84 | LTB4R2 (0.41) | LTB4R2ACHEAGTR1 | |
| SCHEMBL29726873 | 0.82 | LTB4R2 (0.55) | LTB4R2AGTR1 | |
| SCHEMBL21083720 | 0.82 | LTB4R2 (0.55) | LTB4R2AGTR1 | |
| SCHEMBL21125657 | 0.81 | LTB4R2 (0.42) | LTB4R2ACHEAGTR1 | |
| SCHEMBL21083746 | 0.81 | RET (0.39) | ACHE | |
| SCHEMBL21083792 | 0.80 | LTB4R2 (0.43) | LTB4R2ACHEFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11407733-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407733-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | LTB4R2 133/4885SCN9A 2315/4885ACHE 1038/4885 |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | LTB4R2 133/4885SCN9A 2315/4885ACHE 1038/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | LTB4R2 133/4885SCN9A 2315/4885ACHE 1038/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | LTB4R2 133/4885SCN9A 2315/4885ACHE 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.